Skip to content
Inciteful Med

Symptom Management & Quality of Life

Last updated:

ALS symptoms can be effectively managed to protect your comfort and quality of life. Key treatments include Non-Invasive Ventilation for breathing support, PEG tubes for safe nutrition, and targeted medications to relieve muscle cramps, excess saliva, and emotional changes.

Key Takeaways

  • • Non-Invasive Ventilation (NIV) is a critical tool that supports breathing, improves sleep, and can extend survival for people with ALS.
  • • Early placement of a PEG tube ensures safe nutrition and hydration when swallowing becomes difficult and helps prevent weight loss.
  • • Painful muscle cramps and stiffness can be managed with prescribed muscle relaxants and daily physical therapy stretching routines.
  • • Pseudobulbar Affect (PBA), which causes uncontrollable laughing or crying, can be effectively treated with specific FDA-approved medications.
  • • Excess saliva production is common in ALS and can be significantly reduced using oral medications or Botulinum toxin injections.

While ALS currently has no cure, there is a powerful toolkit of treatments and interventions designed to manage your symptoms, protect your comfort, and significantly improve your quality of life. The primary goal of your care team is to stay ahead of the disease, addressing changes before they become overwhelming.

The Cornerstones of Care: Breathing and Nutrition

Two interventions are considered the “gold standard” for supporting patients with ALS because they have been shown to drastically improve daily comfort and extend life.

  • Non-Invasive Ventilation (NIV): Protecting your respiratory health is a top priority in ALS care [1][2]. NIV usually involves wearing a mask connected to a small machine (like a BiPAP) that helps push air into your lungs [3].
    • The Benefit: Using NIV can reduce breathlessness, improve sleep quality, reduce morning headaches, and has been shown to extend survival [3][4][5].
  • PEG Tube (Percutaneous Endoscopic Gastrostomy): As swallowing becomes difficult (dysphagia), it can be hard to get enough calories and hydration [6]. A PEG tube is a small feeding tube placed through the skin into the stomach [7].
    • The Benefit: It helps prevent dangerous weight loss and reduces the risk of aspiration (accidentally breathing food or liquid into the lungs) [8][6]. Doctors often recommend “early” placement to ensure you are strong enough for the simple procedure [9][10].

Managing Physical Symptoms: Cramps and Spasticity

Muscle stiffness (spasticity) and painful muscle cramps are universally experienced by ALS patients and require proactive management to protect mobility and comfort.

  • Treatment: Your doctor may prescribe muscle relaxants like Baclofen, Tizanidine, or Mexiletine for cramps [11][12]. Additionally, daily stretching routines guided by a physical therapist are critical to maintaining joint flexibility and reducing severe stiffness [4][13].

Managing Emotional and Bulbar Symptoms

Living with ALS involves managing unique symptoms that can impact your social life and daily comfort.

  • Pseudobulbar Affect (PBA): This is a condition where you might have sudden, uncontrollable episodes of laughing or crying that don’t match how you actually feel [14].
    • Treatment: Nuedexta (dextromethorphan/quinidine) is an FDA-approved medication specifically indicated for PBA [15]. It has been shown to significantly reduce the frequency and severity of these emotional outbursts [16][17].
  • Sialorrhea (Excess Saliva): Many people with ALS experience drooling or a buildup of saliva, usually because the muscles used for swallowing are weakened [18][19].
    • Treatment: While oral medications (anticholinergics) like glycopyrrolate are often tried first, they can cause side effects like a very dry mouth or constipation [20][21].
    • Botulinum Toxin: Injections of Botulinum toxin (type A or B) into the salivary glands are a highly effective, evidence-based way to reduce saliva production, typically providing relief for 8 to 12 weeks [22][23].

Frequently Asked Questions

When should I start using Non-Invasive Ventilation (NIV) for ALS?
Your doctor will monitor your breathing tests to determine the best time to start NIV. Using it proactively can help reduce breathlessness, improve your sleep quality, and support your overall energy levels.
Why might I need a PEG tube if I have ALS?
As ALS progresses, swallowing can become difficult, leading to weight loss and the risk of choking. A PEG tube is a small feeding tube that helps ensure you receive safe, adequate nutrition and hydration without the strain of swallowing.
What causes uncontrollable laughing or crying in ALS?
This is a condition called Pseudobulbar Affect (PBA), which causes sudden emotional outbursts that don't match your actual feelings. It is a common symptom of ALS and can be effectively treated with specific medications prescribed by your doctor.
How can I manage painful muscle cramps and stiffness from ALS?
Doctors often prescribe muscle relaxants to help relieve severe cramps and muscle spasticity. Daily stretching routines guided by a physical therapist are also essential for maintaining your joint flexibility and overall comfort.
Are there treatments for excess saliva or drooling in ALS?
Yes, excess saliva (sialorrhea) is common when swallowing muscles weaken. It can be managed with oral medications or highly effective Botulinum toxin (Botox) injections into the salivary glands to reduce saliva production.

Questions for Your Doctor

  • • Based on my breathing tests, am I at the point where I should start using Non-Invasive Ventilation (NIV) to protect my sleep and energy?
  • • What is my current rate of weight loss, and at what point would you recommend a PEG tube for nutritional support?
  • • I've noticed I laugh or cry at times that don't match how I feel. Could this be Pseudobulbar Affect (PBA), and is Nuedexta an option for me?
  • • My muscle cramps and stiffness are becoming painful. Can we discuss medications like Baclofen or physical therapy routines to help?
  • • My excess saliva is becoming difficult to manage. Can we discuss Botulinum toxin injections?

Questions for You

  • • How is my breathing, especially when I'm lying flat or after I've been active?
  • • Am I finding it harder to eat enough food or drink enough water throughout the day because of swallowing issues?
  • • Am I experiencing painful muscle spasms or cramps that are interfering with my sleep or daily movement?
  • • Have I experienced any sudden, uncontrollable emotional outbursts that feel "disconnected" from my actual mood?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Motor neuron replacement therapy for amyotrophic lateral sclerosis.

    Liu B, Li M, Zhang L, et al.

    Neural regeneration research 2022; (17(8)):1633-1639 doi:10.4103/1673-5374.332123.

    PMID: 35017408
  2. 2

    Amyotrophic Lateral Sclerosis: New Perpectives and Update.

    Orsini M, Oliveira AB, Nascimento OJ, et al.

    Neurology international 2015; (7(2)):5885 doi:10.4081/ni.2015.5885.

    PMID: 26487927
  3. 3

    Optimizing breathlessness management in amyotrophic lateral sclerosis: insights from a comprehensive systematic review.

    Filipe CB, Carreira NR, Reis-Pina P

    BMC palliative care 2024; (23(1)):100 doi:10.1186/s12904-024-01429-z.

    PMID: 38622643
  4. 4

    Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis.

    Paganoni S, Karam C, Joyce N, et al.

    NeuroRehabilitation 2015; (37(1)):53-68 doi:10.3233/NRE-151240.

    PMID: 26409693
  5. 5

    [Cramps and fasciculations: is it amyotrophic lateral sclerosis?]

    Hübers A, Fayolle D, Ochsner F, et al.

    Revue medicale suisse 2022; (18(779)):790-793 doi:10.53738/REVMED.2022.18.779.790.

    PMID: 35481502
  6. 6

    Percutaneous gastrostomy in amyotrophic lateral sclerosis: a review.

    Castanheira A, Swash M, De Carvalho M

    Amyotrophic lateral sclerosis & frontotemporal degeneration 2022; (23(3-4)):176-189 doi:10.1080/21678421.2021.1946089.

    PMID: 34196236
  7. 7

    Pulmonary scintigraphy as a method to investigate gastrobronchial communication in tracheostomized patients.

    Graziani A, Martelli A, Quercia O, et al.

    Respiratory medicine case reports 2015; (16()):29-31 doi:10.1016/j.rmcr.2015.05.015.

    PMID: 26744647
  8. 8

    Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease.

    Sulistyo A, Abrahao A, Freitas ME, et al.

    The Cochrane database of systematic reviews 2023; (8()):CD004030 doi:10.1002/14651858.CD004030.pub4.

    PMID: 37579081
  9. 9

    Timing and impact of percutaneous endoscopic gastrostomy insertion in patients with amyotrophic lateral sclerosis: a comprehensive analysis.

    Son B, Lee J, Ryu S, et al.

    Scientific reports 2024; (14(1)):7103 doi:10.1038/s41598-024-56752-5.

    PMID: 38531942
  10. 10

    Gastrostomy tube placement is safe in advanced amyotrophic lateral sclerosis.

    Kak M, Issa NP, Roos RP, et al.

    Neurological research 2017; (39(1)):16-22 doi:10.1080/01616412.2016.1259028.

    PMID: 27876446
  11. 11

    A look into the future of ALS research.

    Clerc P, Lipnick S, Willett C

    Drug discovery today 2016; (21(6)):939-49.

    PMID: 26861067
  12. 12

    Amyotrophic Lateral Sclerosis Modifiers in Drosophila Reveal the Phospholipase D Pathway as a Potential Therapeutic Target.

    Kankel MW, Sen A, Lu L, et al.

    Genetics 2020; (215(3)):747-766 doi:10.1534/genetics.119.302985.

    PMID: 32345615
  13. 13

    Supportive care needs of patients with amyotrophic lateral sclerosis/motor neuron disease and their caregivers: A scoping review.

    Oh J, Kim JA

    Journal of clinical nursing 2017; (26(23-24)):4129-4152 doi:10.1111/jocn.13945.

    PMID: 28681543
  14. 14

    Therapeutic Approach of a High Functioning Individual With Traumatic Brain Injury and Subsequent Emotional Volatility With Features of Pathological Laughter and Crying With Dextromethorphan/Quinidine.

    Garcia-Baran D, Johnson TM, Wagner J, et al.

    Medicine 2016; (95(12)):e2886 doi:10.1097/MD.0000000000002886.

    PMID: 27015166
  15. 15

    ALSUntangled #71: Nuedexta.

    Sun Y, Benatar M, Mascías Cadavid J, et al.

    Amyotrophic lateral sclerosis & frontotemporal degeneration 2024; (25(1-2)):218-222 doi:10.1080/21678421.2023.2239292.

    PMID: 37493197
  16. 16

    Efficacy and safety of dextromethorphan/quinidine in treating pseudobulbar affect in neurological disorders: A systematic review and dose-classified network meta-analysis.

    Muneer MA, Tariq I, Zulfiqar E, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026; (47(1)):159.

    PMID: 41530593
  17. 17

    PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.

    Hammond FM, Alexander DN, Cutler AJ, et al.

    BMC neurology 2016; (16()):89 doi:10.1186/s12883-016-0609-0.

    PMID: 27276999
  18. 18

    Sialorrhea in patients with ALS: current treatment options.

    Garuti G, Rao F, Ribuffo V, Sansone VA

    Degenerative neurological and neuromuscular disease 2019; (9()):19-26 doi:10.2147/DNND.S168353.

    PMID: 31118868
  19. 19

    Prevalence of Sialorrhea Among Amyotrophic Lateral Sclerosis Patients: A Systematic Review and Meta-Analysis.

    Wang Y, Yang X, Han Q, et al.

    Journal of pain and symptom management 2022; (63(4)):e387-e396 doi:10.1016/j.jpainsymman.2021.12.005.

    PMID: 34920148
  20. 20

    Efficacy of Botulinum Toxin for Treating Sialorrhea in Neuromuscular Conditions.

    Singh H, Nene Y, Mehta TR, Govindarajan R

    Frontiers in neurology 2020; (11()):513 doi:10.3389/fneur.2020.00513.

    PMID: 32587569
  21. 21

    The Role of Radiation Therapy and Botulinum Toxin Injections in the Management of Sialorrhea in Patients With Amyotrophic Lateral Sclerosis: A Systematic Review.

    Shehee L, O'Rourke A, Garand KL

    Journal of clinical neuromuscular disease 2020; (21(4)):205-221 doi:10.1097/CND.0000000000000273.

    PMID: 32453096
  22. 22

    Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview.

    Petracca M, Guidubaldi A, Ricciardi L, et al.

    Toxicon : official journal of the International Society on Toxinology 2015; (107(Pt A)):129-40.

    PMID: 26327120
  23. 23

    Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.

    James E, Ellis C, Brassington R, et al.

    The Cochrane database of systematic reviews 2022; (5()):CD006981 doi:10.1002/14651858.CD006981.pub3.

    PMID: 35593746

This page provides informational content about managing ALS symptoms and does not replace professional medical advice. Always consult your neurologist or ALS care team before starting or changing any treatments.

Stay up to date

Get notified when new research about Amyotrophic lateral sclerosis is published.

No spam. Unsubscribe anytime.